Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review

Executive Summary

CMS’ Medicare Evidence Development and Coverage Advisory Committee is scheduled to meet Sept. 21 to consider whether use of anti-VEGF drugs, including Roche’s Avastin (bevacizumab) and Roche/Genentech’s Lucentis (ranibizumab), are “reasonable and necessary” for treatment of diabetic macular edema.

You may also be interested in...



MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012

Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.

MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012

Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.

Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin

Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.

Related Content

Topics

UsernamePublicRestriction

Register

PS053637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel